Skip to main content
. Author manuscript; available in PMC: 2017 Sep 21.
Published in final edited form as: Bioconjug Chem. 2016 Sep 2;27(9):2157–2165. doi: 10.1021/acs.bioconjchem.6b00374

Figure 5.

Figure 5

Evaluation of NKlRL-Peptide-LS288 accumulation in the internal tissues and organs of the mice shown in Figure 4. Mice implanted with a NK1R tumor (a-d) and KB tumor (e-f) was injected NKlRL-Peptide-LS288 in the absence (a, b; e, f) or presence (c, d) of 100-fold excess of base ligand to block all vacant receptor binding sites.